ANVS vs APVO

Annovis Bio, Inc. vs Aptevo Therapeutics Inc. — Valuation Comparison 2026

ANVS

Biotechnology
Annovis Bio, Inc.
Quality
3.9
out of 10
Value Trap
24
SAFE
Price
$1.90
Last close
Models
7/13
Active
VS

APVO

Biotechnology
Aptevo Therapeutics Inc.
Quality
4.2
out of 10
Value Trap
24
SAFE
Price
$5.00
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType ANVS Fair ValueANVS Upside APVO Fair ValueAPVO Upside
Bayesian DCF Intrinsic $0.69 -63.6% $6.12 +22.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.03 -98.3% $0.36 -92.6%
Dynamic NAV Asset-Based $0.93 -51.1%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ANVS vs APVO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ANVS vs APVO — Which Stock Is More Undervalued?

APVO scores higher with a 4.2/10 quality rating vs ANVS's 3.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Annovis Bio, Inc. (ANVS) and Aptevo Therapeutics Inc. (APVO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ANVS currently trades at $1.90 with a QOC of 3.9/10, while APVO trades at $5.00 with a QOC of 4.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).